Current Vascular Pharmacology
Title:Editorial: Bivalirudin and the Matrix Trial: The End of the Story?
Volume: 14 Issue: 1
Author(s): Giuseppe De Luca and Harry Suryapranata
Affiliation:
Export Options
About this article
Cite this article as:
De Luca Giuseppe and Suryapranata Harry, Editorial: Bivalirudin and the Matrix Trial: The End of the Story?, Current Vascular Pharmacology 2016; 14 (1) . https://dx.doi.org/10.2174/157016111401151126161132
DOI https://dx.doi.org/10.2174/157016111401151126161132 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
28
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Gene Therapy: Therapeutic Potential and Current Progress
Current Gene Therapy Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology Vasopressin in Liver Disease – Should We Turn On or Off?
Current Clinical Pharmacology Inflammatory Biomarkers Predicting Events in Atherosclerosis
Current Medicinal Chemistry Safety of Spinal Anesthesia in a Patient with Achondroplasia for Cesarean Section
Current Drug Safety Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) Intracoronary Injection of Drugs to Treat No – Reflow Phenomenon and Microcirculatory Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Renal Artery Stenting: Efficacy and Complications
Current Hypertension Reviews Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Design and Optimization of a Chronotherapeutic Dosage Form for Treatment of Nocturnal Acid Breakthrough
Current Drug Delivery Modulation of Collagen Turnover in Cardiovascular Disease
Current Pharmaceutical Design Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Role of Bone-Type Tissue-Nonspecific Alkaline Phosphatase and PHOSPO1 in Vascular Calcification
Current Pharmaceutical Design Inflammatory Cardiovascular Risk Markers in Obstructive Sleep Apnoea Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation Ceruloplasmin, the Unique Multi-Copper Oxidase of Vertebrates
Protein & Peptide Letters Effects of Thiazolidinediones on Coronary Artery Disease: Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Implications of microRNAs in the Pathogenesis of Atherosclerosis and Prospects for Therapy
Current Drug Targets PET Imaging and Coronary Circulatory Function: Non-Invasive Mechanistic Insights and Cardiovascular Prognosis
Current Cardiology Reviews